

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over [ID6372]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- |    |  |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

One stakeholder noted that Black, Asian and minority ethnic people with cystic fibrosis are less likely to be eligible for current CFTR modulators as they are more likely to have rare mutations.
--

- |    |  |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation. The committee can only consider treatments within their marketing authorisation.
---

- |    |   |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No
----

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No	

**Approved by Associate Director (name):** ...Lorna Dunning.....

**Date:** 07/01/2025